Neuroendocrine, Immune, and Local Responses Related to Temporomandibular Disorders

Orofacial pain frequently originates from pathologic conditions in the masticatory muscles or temporomandibular joints (TMJs). The mediators and mechanisms that monitor pain and inflammation, centrally or peripherally, are of great interest in the search for new treatment modalities. The neuropeptides substance P (SP), calcitonin gene-related peptide (CGRP), and neuropeptide Y (NPY) have all been found at high levels in the synovial fluid of arthritic TMJs in association with spontaneous pain, while serotonin (5-HT) has been found in association with hyperalgesia/allodynia of the TMJ. Interleukin-1β (IL-1β) and tumor necrosis factor α (TNFα) have been found in arthritic TMJs, but not in healthy TMJs, in association with hyperalgesia/allodynia of the TMJ as well as spontaneous pain. Anterior open bite, which may be a clinical sign of TMJ destruction, has been found in association with high levels of CGRP, NPY, and IL-1β in the synovial fluid of the TMJ. Interleukin-1β has also been related to radiographic signs of joint destruction. Prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) are both present in the arthritic TMJ, and PGE2 has been shown to be associated with hyperalgesia/allodynia of the TMJ. Very little is known about pain and inflammatory mediators in muscles. However, we know that 5-HT and PGE2 are involved in the development of pain and hyperalgesia/allodynia of the masseter muscle in patients with fibromyalgia, whereas local myalgia (myofascial pain) seems to be modulated by other, as yet unknown mediators. Interaction between the peripheral nervous system (sensory and sympathetic nerves), the immune system, and local cells is probably of great importance for the modulation of pain and inflammation in the TMJ and orofacial musculature.

arthritis; cytokines; eicosanoids; inflammation; masticatory muscles; myalgia; neuropeptides; pain; serotonin; synovial fluid; temporomandibular disorders; temporomandibular joint

1. Kopp S. The influence of neuropeptides, serotonin, and interleukin-1β on temporomandibular joint pain and inflammation. J Oral Maxillofac Surg 1998;56:189–191.

2. Alstergren P, Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E. Determination of temporomandibular joint fluid concentrations using vitamin B12 as an internal standard. Eur J Oral Sci 1995;103:214–218.

3. Alstergren P, Appelgren A, Appelgren B, Kopp S, Nordahl S, Theodorsson E. Measurement of joint aspirate dilution by a spectrophotometer capillary tube system. Scand J Clin Lab Invest 1996;56:415–420.

4. Buck SH, Walsh JH, Yamamura HT. Neuropeptides in sensory neurons. Life Sci 1982;30:1857–1866.

5. Bisset GW, Lewis GP. Spectrum of pharmacological activity in some biologically active peptides. Br J Pharmacol 1962;9:168–182.

6. Juan H, Sametz W. Histamine-induced release of arachidonic acid and of prostaglandins in the peripheral vascular bed. Arch Pharmacol 1980;314:183–190.

7. Nakamura-Craig M, Smith TW. Substance P and peripheral inflammatory hyperalgesia. Pain 1989;38:91–98.

8. Rosen A, Brodin E. Effect of acute morphine treatment on peptide levels in the periaqueductal grey. Acta Physiol Scand 1989;136:493–494.

9. Kopf WC, Dunegan MA. Modulation of macrophage-mediated tumoricidal activity by neuropeptides and neurohormones. J Immunol 1985;135:350–354.

10. Laurenzi AMA, Persson MAA, Dalsgaard CJ, Ringden O. Stimulation of human B lymphocyte differentiation by the neuropeptides, substance P and neurokinin A. Scand Immunol 1989;30:695–702.

11. Matsuda H, Kawakita K, Kiso Y, Nakano T, Kitamura Y. Substance P-induced granulocyte infiltration through degranulation of mast cells. J Immunol 1989;142:927–931.

12. Ohlen A, Thureson-Klein A, Lindbom L, Persson MG, Hedqvist P. Substance P activates leukocytes and platelets in rabbit microvessels. Blood Vessels 1989;26:84–94.

13. Lotz M, Carson DA, Vaughan JH. Substance P activation of rheumatoid synoviocytes. Science 1987;235:893–895.

14. Kimball ES, Persico FJ, Vaught JL. Substance P, neurokinin A and neurokinin B induce generation of IL-1–like activity in P338D1 cells. Immunol 1988;141:3564–3569.

15. Johansson AS, Isacsson G, Isberg A, Granholm AC. Distribution of substance P-like immunoreactive nerve fibers in temporomandibular joint soft tissues of monkey. Scand J Dent Res 1986;94:225–230.

16. Oohkubo T, Shibata M, Yamada Y, Kaya H, Takahashi

H. Role of substance P in neurogenic inflammation in the rat incisor pulp and the lower lip. Arch Oral Biol 1993;38:151–158.

17. Lembeck F, Donnerer J, Tsuchiya M, Nagahisa A. The nonpeptide tachykinin antagonist, CP-96, 345, is a potent inhibitor of neurogenic inflammation. Br J Pharmacol 1992;105:527–530.

18. Appelgren A, Appelgren B, Eriksson S, Kopp S, Lundeberg T, Nylander M, Theodorsson E. Neuropeptides in temporomandibular joints with rheumatoid arthritis: A clinical study. Scand J Dent Res 1991;99:519–521.

19. Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E. Neuropeptides in the arthritic TMJ and symptoms and signs from the stomatognathic system with special consideration to rheumatoid arthritis. J Orofac Pain 1995;9:215–225.

20. Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E. Substance P–associated increase of intraarticular temperature and pain threshold in the arthritic TMJ. J Orofac Pain 1998;12:101–107.

21. Åkerman S, Kopp S. Intra-articular and skin surface temperature of human temporomandibular joint. Scand J Dent Res 1987;95:493–498.

22. Åkerman S, Kopp S. Intra-articular and skin surface temperature of the temporomandibular joint in patients with rheumatoid arthritis. Acta Odontol Scand 1988;46:41–48.

23. Alstergren P, Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E. Co-variation of neuropeptide Y, calcitonin gene-related peptide, substance P and neurokinin A in joint fluid from patients with temporomandibular joint arthritis. Arch Oral Biol 1995; 40:127–135.

24. Lundberg JM, Franco-Cereceda A, Hua XY, Hokfelt T, Fischer JA. Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur J Pharmacol 1985; 108:315–319.

25. Holzer P. Local effector functions of capsaicin-sensitive sensory nerve endings: Involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 1988;24:739–768.

26. Raud J, Lundeberg T, Brodda-Jansen G, Theodorsson E, Hedqvist P. Potent anti-inflammatory action of calcitonin gene-related peptide. Biochem Biophys Res Commun 1991;180:1429–1435.

27. Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E. Relation between the intra-articular temperature of the arthritic temporomandibular joint and presence of calcitonin gene-related peptide in the joint fluid—A clinical study. Acta Odontol Scand 1993;51:285–291.

28. Goodman EC, Iversen LL. Calcitonin gene-related peptide: Novel neuropeptide. Life Sci 1986;38:2169–2178.

29. Larsson J, Ekblom A, Henriksson K, Lundeberg T, Theodorsson E. Concentration of substance P, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scand J Rheumatol 1991;20:326–335.

30. Lundberg JM, Terenius L, Hökfelt T, Martling C-R, Tatemoto K, Mutt V, et al. Neuropeptide Y (NPY) -like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand1982;116:477–480.

31. Wahlestedt C, Grundemar L, Håkanson R, Heilig M, Shen GH, Zukowska-Grojec Z, Reis DJ. Neuropeptide Y receptor subtypes, Y1 and Y2. Ann N Y Acad Sci 1990; 611:7–26.

32. Modin A, Pernow J, Lundberg JM. Sympathetic regulation of skeletal muscle blood flow in the pig: A non-adrenergic component likely to be mediated by neuropeptide Y. Acta Physiol Scand 1993;148:1–11.

33. Takahashi T, Ichinose M, Yamauchi H, Miura M, Nakajima N, Ishikawa J, et al. Neuropeptide Y inhibits neurogenic inflammation in guinea pig airways. J Appl Physiol 1993;75:103–107.

34. Wahlestedt C, Reis DJ. Neuropeptide Y-related peptides and their receptors—Are the receptors potential therapeutic drug targets? Ann Rev Pharmacol Toxicol 1993; 32:309–352.

35. Ichikawa H, Wakisaka S, Matsuo S, Akai M. Peptidergic innervation of the temporomandibular disk in the rat. Experientia 1989;45:303–304.

36. Levine JD, Dardick SJ, Roizen MF, Helms C, Basbaum AI. Contribution of sensory afferents and sympathetic efferent to jointinjury in experimental arthritis. J Neurosci 1986;6:3423–3429.

37. Larsson J, Ekblom A, Henriksson K, Lundeberg T, Theodorsson E. Immunoreactive tachykinins, calcitonin gene-related peptide and neuropeptide Y in human synovial fluid from inflamed joints. Neurosci Lett 1989;100:326–330.

38. Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E. Relation between the intra-articular temperature of the temporomandibular joint and the presence of neuropeptide Y-like immunoreactivity in the joint fluid. Acta Odontol Scand 1993;51:1–8.

39. Alstergren P, Appelgren A, Appelgren B, Kopp S, Lundeberg T, Theodorsson E. The effect on joint fluid concentration of neuropeptide Y by intra-articular injection of glucocorticoid in temporomandibular joint arthritis. Acta Odontol Scand 1995;54:1–7.

40. Alstergren P, Ernberg M, Kopp S, Lundeberg T, Theodorsson E. TMJ pain in relation to circulating neuropeptide Y, serotonin and interleukin-1􀀁 in rheumatoid arthritis. J Orofac Pain 1999;13:49–55.

41. Basbaum AI, Levine JD. The contribution of the nervous system to inflammation and inflammatory disease. Can J Physiol Pharmacol 1991;69:647–651.

42. Alsip NL, Harris PD. Receptor mediation of microvascular responses to serotonin in striated muscle. Am J Physiol 1991;261:H1525–H1533.

43. Cailliet R (ed). Soft Tissue Pain and Disability, ed 2. Philadelphia: F. A. Davis, 1988:31.

44. Eide P-K, Hole K. The role of 5-hydroxytryptamine (5-HT) receptor subtypes and plasticity in the 5-HT systems in the regulation of nociceptive sensitivity. Cephalalgia 1993;13:75–85.

45. Grubb BD, McQueen DS, Iggo A, Birrell GJ, Dutia MB. A study of 5-HT receptors associated with afferent nerves located in normal and inflamed rat ankle joints. Agents Actions 1988;25:216–218.

46. Birrell GJ, McQueen DS, Iggo A, Grubb BD. The effects of 5-HT on articular sensory receptors in normal and arthritic rats. Br J Pharmacol 1990;101:715–721.

47. Taiwo YO, Levine JD. Serotonin is a directly acting hyperalgesic agent in the rat. Neuroscience 1992;48:485–490.

48. Carraway RE, Cochrane DE, Granier C, Kitabgi P, Leeman E, Singer EA. Parallel secretion of endogenous 5-hydroxytryptamine and histamine from mast cells stimulated by vasoactive peptides and compound 48/80. Br J Pharmacol1984;81:227–229.

49. Endresen GK. Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis. Rheumatol Int 1989;9:19–24.

50. Weissbarth E, Baruth B, Mielke H, Liman W, Deicher H. Platelets as target cells in rheumatoid arthritis and systemic lupus erythematosus: A platelet-specific immunoglobulin inducing the release reaction. Rheumatol Int 1982;2:67–73.

51. Zeller J, Weissbarth E, Baruth B, Mielke H, Deicher H. Serotonin content of platelets in inflammatory rheumatic diseases. Correlation with clinical activity. Arthritis Rheum 1983;26:532–540.

52. McKay DM, Bienenstock J. The interaction between mast cells and nerves in the gastrointestinal tract. Immunol Today 1994;15:533–538.

53. Rueff A, Dray A. 5-hydroxytryptamine-induced sensitization and activation of peripheral fibres in the neonatal rat are mediated via different 5-hydroxytryptamine receptors. Neuroscience 1992;50:899–905.

54. Herbert MK, Schmidt RF. Activation of normal and inflamed fine articular afferent units by serotonin. Pain 1992;50:79–88.

55. Gyermek L. Pharmacology of serotonin as related to anesthesia. J Clin Anesth 1996;8:402–425.

56. Richardson BP, Engel G. The pharmacology and function of 5HT3 receptors. Trends Neurosci 1986;9:424–428.

57. Martin GR, Humphrey PP. Receptors for 5-hydroxytryptamine: Current perspectives on classification and nomenclature. Neuropharmacol 1994;33:261–273.

58. Giordano J, Dyche J. Differential analgesic actions of serotonin 5HT3 receptor antagonists in the mouse. Neuropharmacol 1989;28:423–427.

59. Giordano J, Rogers LV. Peripherally administered serotonin 5HT3 receptor antagonists reduce inflammatory pain in rats. Eur J Pharmacol 1989;170:83–86.

60. Alstergren P, Kopp S. Pain and synovial fluid concentration of serotonin in arthritic temporomandibular joints. Pain 1997;72:137–143.

61. Alstergren P, Kopp S, Theodorsson E. Synovial fluid sampling from the temporomandibular joint: Sample quality criteria and levels of interleukin-1􀀁 and serotonin. Acta Odontol Scand 1999;57:16–22.

62. Stratz T, Samborski W, Hrycaj P, Pap T, Mackiewicz S, Mennet P, Müller W. Die Serotoninkonzentration im Serum bei Patienten mit generalisierter Tendomyopathie (Fibromyalgie) und chronischer Polyarthritis. Med Klin 1993;88:458–462.

63. Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol 1997;24:555–559.

64. Ernberg M, Hedenberg-Magnusson B, Alstergren P, Kopp

S. The level of serotonin in the superficial masseter muscle in relation to local pain and allodynia. Life Sci 1999;65:313–325.

65. Abramovici A, Daizade I, Yosipovitch Z, Gibson SJ, Polak JM. The distribution of peptide-containing nerves in the synovia of the cat knee joint. Histol Histopathol 1991;6:469–476.

66. Ernberg M, Hedenberg-Magnusson B, Alstergren P, Kopp

S. Effect of local glucocorticoid injection on masseter muscle level of serotonin in patients with chronic myalgia. Acta Odontol Scand 1998;56:129–134.

67. Henriksson KG, Bengtsson A. Fibromyalgia: A clinical entity? Can J Physiol Pharmacol 1991;69:672–677.

68. Larsson SE, Bengtsson A, Bodegård L, Henriksson KG, Larsson J. Acta Orthop Scand 1988;59:552–556.

69. Hedenberg-Magnusson B, Ernberg M, Kopp S. Symptoms and signs of temporomandibular disorders in patients with fibromyalgia andlocal myalgia of the temporomandibular system—A comparative study. Acta Odontol Scand 1997;6:344–349.

70. Frishman WH, Huberfeld S, Okin S, Wang YH, Kumar A, Shareef B. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol 1995;35:541–572.

71. Kurita H, Ernberg M, Tominaga K, Alstergren P, Kopp S. The effect of 5-hydroxytryptamine-2 and 􀀂-adrenergic receptor antagonists on 5-hydroxytryptamine-induced decrease in rabbit masseter muscle blood flow. Arch Oral Biol 1999;44:651–656.

72. Ernberg M, Hedenberg-Magnusson B, Alstergren P, Kopp

S. Short-term effect of glucocorticoid injection into the superficial masseter muscle of patients with chronic myalgia. J Orofac Pain 1997;11:249–257.

73. Ernberg M, Lundeberg T, Kopp S. Pain and allodynia/hyperalgesia induced by intramuscular injection of serotonin in patients with fibromyalgia and healthy individuals. Pain 2000;85:31–39.

74. Jensen K, Tuxen C, Pedersen-Bjergaard U, Jansen I, Edvinsson L, Olesen J. Pain and tenderness in human temporal muscle induced by bradykinin and 5-hydroxytryptamine. Peptides 1990;11:1127–1132.

75. Ernberg M, Lundeberg T, Kopp S. Effect of propranolol and granisetron on experimentally induced pain and allodynia/hyperalgesia by intramuscular injection of serotonin into the human masseter muscle. Pain 1999;83:1–8.

76. Ito H, Hidaka K, Miyata K, Kamato T, Nishida A, Honda

K. Characterization of YM060, a potent and selective 5-hydroxytryptamine3 receptor antagonist, in rabbit nodose ganglion and NlE-115 neuroblastoma cells. J Pharmacol Exp Ther 1992;263:1127–1132.

77. Fletcher A, Cliffe IA, Dourish CT. Silent 5-HT1A receptor antagonists: Utility as research tools and therapeutic agents. Trends Pharmacol Sci 1993;14:41–48.

78. Giordano J, Daleo C, Sacks SM. Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans. Eur J Pharmacol 1998;354:R13–R14.

79. Hrycaj P, Stratz T, Mennet P, Müller W. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome—A preliminary study. J Rheumatol 1996;23:1418–1423.

80. Lautenbacher S, Rollman GB. Sex differences in responsiveness to painful and non-painful stimuli are dependent upon the stimulation method. Pain 1993;53:255–264.

81. Berkley KJ. Sex differences in pain. Behav Brain Sci 1997;20:371–380.

82. Ernberg M, Hedenberg-Magnusson B, Alstergren P, Lundeberg T, Kopp S. Pain, allodynia, and serum serotonin level in orofacial pain of muscular origin. J Orofac Pain 1999;13:56–62.

83. Moldofsky H, Warsh JJ. Plasma tryptophan and musculoskeletal pain in non-articular rheumatism (“fibrositis syndrome”). Pain 1978;5:65–71.

84. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550–556.

85. Ernberg M, Voog Ü, Alstergren P, Lundeberg T, Kopp S. Plasma and serum serotonin levels and their relationship to orofacial pain and anxiety in fibromyalgia. J Orofac Pain 2000;14:37–46.

86. Krag NJ, Nørregaard J, Hindberg I, Larsen JK, Danneskiold-Samsøe B. Psychopathology measured by established self-rating scales and correlated to serotonin measures in patients with fibromyalgia. Eur Psychiatry 1995;10:404–409.

87. Glover V, Jarman J, Sandler M. Migraine and depression: Biological aspects. J Psychiatr Res 1993;27:223–231.

88. Duff GW. Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol Suppl 1994;100:9–19.

89. Verbruggen G, Veys EM, Malfait AM, De Clerq L, Van den Bosch F, de Vlam K. Influence of human recombinant interleukin-1 beta on human articular cartilage. Mitotic activity and proteoglycan metabolism. Clin Exp Rheumatol 1991;9:481–488.

90. Elson CJ, Thompson SJ, Westacott CI, Bhoola KD. Mediators of joint swelling and damage in rheumatoid arthritis and pristane induced arthritis. Autoimmunity 1992;13:327–331.

91. Kubota E, Imamura H, Kubota T, Shibata T, Murakami

K. Interleukin-1 beta and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. J Oral Maxillofac Surg 1997;55:20–27.

92. Dinarello CA. Interleukin-1. Rev Infect Dis 1984;6:51–95.

93. Kimball ES, Fisher MC. Potentiation of IL-1-induced BALB/3T3 fibroblast proliferation by neuropeptides. J Immunol 1988;141:4203–4208.

94. Saklatvala J, Sarsfield SJ, Townsend Y. Pig interleukin-1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J Exp Med 1985;162:1208–1222.

95. Dinarello CA. The biological properties of interleukin-1. Eur Cytokine Netw 1994;5:517–531.

96. Dinarello CA. Interleukin-1. Dig Dis Sci 1988;33:25S–35S.

97. Ruschen S, Lemm G, Warnatz H. Spontaneous and LPS-stimulated production of intracellular IL-1 beta by synovial macrophages in rheumatoid arthritis is inhibited by IFN-gamma. Clin Exp Immunol 1989;76:246–251.

98. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095–2147.

99. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Intern Rev Immunol 1998;16:457–499.

100. Arend WP, Malyak M, Smith MF, Whisenand TD, Slack JL, Sims JE, et al. Binding of IL-1􀀂, IL-1􀀁 and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 1994;153:4766–4774.

101. Rooney M, Symons JA, Duff GW. Interleukin-1 beta in synovial fluid is related to local disease activity in rheumatoid arthritis. Rheumatol Int 1990;10:217–219.

102. Ferreira SH, Lorenzetti BB, Bristow AF, Poole S. Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 1988;334:698–700.

103. Jeanjean AP, Moussaoui SM, Maloteaux JM, Laduron PM. Interleukin-1 beta induces long-term increase of axonally transported opiate receptors and substance P. Neurosci 1995;68:151–157.

104. Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF. Characterization of cytokine-induced hyperalgesia. Brain Res 1994;654:15–26.

105. Alstergren P, Ernberg M, Kvarnström M, Kopp S. Interleukin-1β in synovial fluid from the arthritic temporomandibular joint and its relation to pain, mobility and anterior open bite. J Oral Maxillofac Surg 1998;56:1059–1065.

106. Grassi J, Roberge CJ, Frobert Y, Pradelles P, Poubelle PK. Determination of IL1 alpha, IL1 beta and IL2 in biological media using specific enzyme immunometric assays. Immunol Rev 1991;119:125–145.

107. Holt I, Cooper RG, Denton J, Meager A, Hopkins SJ. Cytokine inter-relationships and their association with disease activity in arthritis. Br J Rheum 1992;31:725–733.

108. Nordahl S, Alstergren P, Eliasson S, Kopp S. Interleukin-1 beta in plasma and synovial fluid in relation to radiographic changes in arthritic temporomandibular joints. Eur J Oral Sci 1998;106:559–563.

109. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 1988;ii:706–709.

110. Bertazzolo N, Punzi L, Stefani MP, Cesaro G, Pianon M, Finco B, Todesco S. Interrelationships between interleukin (IL) -1, IL-6 and IL-8 in synovial fluid of various arthropathies. Agents Actions 1994;41:90–92.

111. Kubota E, Imamura H, Kubota T, Shibata T, Murakami K. Interleukin-1β and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. J Oral Maxillofac Surg 1997;55:20–27.

112. Larheim TA, Storhaug K, Tveito L. Temporomandibular joint involvement and dental occlusion in a group of adults with rheumatoid arthritis. Acta Odontol Scand 1983;41:301–309.

113. Åkerman S, Kopp S, Nilner M, Petersson A, Rohlin M. Relationship between clinical and radiologic findings of the temporomandibular joint in rheumatoid arthritis. Oral Surg Oral Med Oral Pathol 1988;66:639–643.

114. Nordahl S, Alstergren P, Appelgren A, Appelgren B, Eliasson S, Kopp S. Pain, tenderness, reduced mobility and anterior open bite in relation to radiographic change in temporomandibular disease. Acta Odontol Scand 1997;55:18–22.

115. Eastgate JA, Symons JA, Wood NC, Capper SJ, Duff GW. Plasma levels of interleukin-1-alpha in rheumatoid arthritis. Br J Rheumatol 1991;30:295–297.

116. North J, Situnayake RD, Tikly M, Cremona A, Nicoll J, Kumararatne DS, Nuki G. Interleukin-1 beta, hand and foot mineral content, and the development of joint erosions in rheumatoid arthritis. Ann Rheum Dis 1994;53:543–546.

117. Jouvenne P, Vannier E, Dinarello CA, Miossec P. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis. Arthritis Rheum 1998;41:1083–1089.

118. Feldmann M, Brennan FM, Field M, Maini RN. Pathogenesis of rheumatoid arthritis: Cellular and cytokine interactions. In: Smolen JS, Kalden JR, Maini RN (eds). Rheumatoid Arthritis. Berlin, Heidelberg: Springer-Verlag, 1992:41–54.

119. Philip R, Epstein LB. Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, 􀀃-interferon and interleukin-1. Nature 1986;323:86–89.

120. Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041–1045.

121. Westacott CI, Whicher JT, Barnes IC, Thompson D, Swan AJ, Dieppe PA. Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis 1990;49:676–681.

122. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125–1132.

123. Di Giovine FS, Nuki G, Duff GW. Tumour necrosis factor in synovial exudates. Ann Rheum Dis 1988;47:768–772.

124. Neidel J, Schulze M, Lindschau J. Association between degree of bone-erosion and synovial fluid levels of tumor necrosis factor alpha in the knee joints of patients with rheumatoid arthritis. Inflamm Res 1995;44:217–221.

125. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997;24:518–523.

126. Shafer DM, Assael L, White LB, Rossomando EF. Tumor necrosis factor-alpha as a biochemical marker of pain and outcome in temporomandibular joints with internal derangements. J Oral Maxillofac Surg 1994;52:786–791.

127. Fu K, Ma X, Zhang Z, Chen W. Tumor necrosis factor in synovial fluid of patients with temporomandibular disorders. J Oral Maxillofac Surg 1995;53:424–426.

128. Sandler NA, Buckley MJ, Cillo JE, Braun TW. Correlation of inflammatory cytokines with arthroscopic findings in patients with temporomandibular joint internal derangements. J Oral Maxillofac Surg 1998;56:534–543.

129. Takahashi T, Kondoh T, Fukuda M, Yamazaki Y, Toyosaki T, Suzuki R. Proinflammatory cytokines detectable in synovial fluids from patients with temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:135–141.

130. Nordahl S, Alstergren P, Kopp S. Tumor necrosis factor α in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain. J Oral Maxillofac Surg 2000; 58:525–530.

131. Campbell IK, Piccoli DS, Roberts MJ, Muirden KD, Hamilton JA. Effects of tumor necrosis factor α and β on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum 1990;33:542–552.

132. Maini RN, Brennan FM, Williams R, Chu CQ, Cope AP, Gibbons D, Elliott M, Feldman M. TNF-α in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheum 1993;11:173–175.

133. Vilcek J, Lee TH. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991;266:7313–7316.

134. Wagner R, Myers RR. Schwann cells produce tumour necrosis factor alpha: Expression in injured and non-injured nerves. Neuroscience 1996;73:625–629.

135. Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH. The pivotal role of tumor necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 1992;107:660–664.

136. Watkins LR, Goehler LE, Relton J, Brewer MT, Maier SF. Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. Brain Res 1995;692:244–250.

137. Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ. Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 1995;115:1265–1275.

138. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: The contribution of tumor necrosis factor alpha. Br J Pharmacol 1997;121:417–424.

139. Sorkin LS, Xiao WH, Wagner R, Myers RR. Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibers. Neurosci 1997;81:255–262.

140. Elliot M, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosisfactor 􀀂. Arthritis Rheum 1993;36:1681–1690.

141. Davies P, MacIntyre E. Prostaglandins and inflammation. In: Gallin JI, Goldstein IM, Snyderman R (eds). Inflammation: BasicPrinciples and Clinical Correlates. New York: Raven Press, 1992:123–142.

142. Wittenberg RH, Willburger RE, Kleemeyer KS, Peskar BA. In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum 1993;36:1444–1450.

143. Cailliet R. Myofascial pain syndromes. In: Cailliet R (ed). Head and Face Pain Syndromes. Philadelphia: F. A. Davis, 1992:100–124.

144. Flower RJ, Blackwell GJ. The importance of phospholipase A2 in prostaglandin biosynthesis. Biochem Pharm 1976;225:285–291.

145. McLennan IS, Macdonald RE. Prostaglandin synthetase and prostacyclin synthetase in mature rat skeletal muscles: Immunohistochemical localization to arterioles, tendons and connective tissues. J Anat 1991;178:243–253.

146. Wilson JR, Kapoor SC. Contribution of prostaglandins to exercise-induced vasodilation in humans. Am J Physiol 1993;265:171–175.

147. Hirata F, Schiffman E, Venkatasubramanian K, Salomon D, Axelrod J. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Nat Acad Sci USA 1980;77:2533–2536.

148. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs: Differences and similarities. N Engl J Med 1991;324:1716–1725.

149. Chromatic JA, Vandenburgh HH. Mechanical stimulation of skeletal muscle cells mitigates glucocorticoid-induced decreases in prostaglandin production and prostaglandin synthetase activity. J Cell Physiol 1994;159:407–414.

150. Gibson JN, Poyser NL, Morrison WL, Scrimgeor CM, Rennies MJ. Muscle protein synthesis in patients with rheumatoid arthritis: Effect of chronic corticosteroid therapy on prostaglandin F2 alpha availability. Eur J Clin Invest 1991;21:406–412.

151. Fedyk ER, Philips RP. Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B-lymphocytes to IgE-secreting cells. Proc Natl Acad Sci USA 1996;93:10978–10983.

152. Levine JD, Taiwo YO. Hyperalgesic pain: A review. Anesth Prog 1990;37:133–135.

153. Gallin JI, Goldstein IM, Snyderman R. Inflammation: Basic principles and clinical correlates. In: Gallin JI, Goldstein IM, Snyderman R (eds). Inflammation: Basic Principles and Clinical Correlates. New York: Raven Press, 1992:1–4.

154. Quinn JH, Bazan NG. Identification of prostaglandin E2 and leukotriene B4 in the synovial fluid of painful, dysfunctional temporomandibular joints. J Oral Maxillofac Surg 1990;48:968–971.

155. Murakami KI, Shibata T, Kubota E, Maeda H. Intra-articular levels of prostaglandin E2, hyaluronic acid, and chondroitin-4 and -6 sulfates in the temporomandibular joint synovial fluid of patients with internal derangement. J Oral Maxillofac Surg 1998;56:199–203.

156. Prete PE, Gurakar-Osborne A. The contribution of synovial fluid lipoproteins to the chronic synovitis of rheumatoid arthritis. Prostaglandins 1997;54:689–698.

157. Alstergren P, Kopp S. Prostaglandin E2 in synovial fluid from the arthritic temporomandibular joint and its relation to pain.J Oral Maxillofac Surg 2000;58:180–186.

158. Brendstrup P. Late edema after muscular exercise. Arch Physiol Med 1962;43:401–405.

159. Ahmadzadeh N, Shingu M, Nobunaga M, Tawara T. Relationship between leukotriene B4 and immunological parameters in rheumatoid synovial fluids. Inflammation 1991;15:497–503.

160. Lam BK, Austen KF. Leukotrienes: Biosynthesis, release and actions. In: Gallin JI, Goldstein IM, Snyderman R (eds). Inflammation: Basic Principles and Clinical Correlates. New York: Raven Press, 1992:139–147.

161. Davidson EM, Rae SA, Smith MJ. Leukotriene B4 in synovial fluid. J Pharm Pharmacol 1982;34:410.

162. Kageyama Y, Koide Y, Miyamoto S, Yoshida TO, Inoue

T. Leukotriene B4-induced interleukin-1 beta in synovial cells from patients with rheumatoid arthritis. Scand J Rheumatol 1994;23:148–150.

163. Samuelsson B. Arachidonic metabolism: Role in inflammation. Rheumatol 1991;1:3–6.

164. Samuelsson B, Dahlen S-E, Lindgren JÅ, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: Structures, biosynthesis and biological effects. Science 1987;237:1171–1176.

165. Thomsen MK, Ahnfeldt-Ronne I. Leukotrienes. A review of the significance for disease in man and the possibilities for the therapeutic intervention [in Danish]. Ugeskr Laeger 1991;153:173–176.

166. Costello PB, Baer AN, Green FA. Lipoxygenase products in inflammatory synovial fluids and other exudates. Ann Rheum Dis 1992;51:1215–1218.

167. Takamoto M, Yano T, Shintani T, Hiraku S. A highly sensitive and selective method for the determination of leukotriene B4 in human plasma by negative ion chemical ionization/gas chromatography/tandem mass spectrometry. J Pharm Biomed Anal 1995;13:1465–1472.

168. Shindo K, Fukumura M, Miyakawa K. Leukotriene B4 levels in the arterial blood of asthmatic patients and the effects of prednisolone.Eur Respir J 1995;8:605–610.